An observational study in Noninfectious Uveitis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 1 Day to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Chronic, noninfectious uveitis in children, associated with various systemic inflammatory diseases, carries a high risk of vision loss. Intestinal dysbiosis and the translocation of bacterial peptidoglycans (PG) that activate innate receptors recognizing PG could represent a common initiating mechanism, independent of the underlying disease. Studying these biological signatures in comparative cohorts could lead to a better understanding of the onset of uveitis and the development of targeted diagnostic and therapeutic strategies.
The objectives of this project are to characterize the peptidoglycan (PG) signature in healthy children and in the context of pediatric noninfectious uveitis; to compare the peptidoglycan signatures of patients with noninfectious uveitis to those with pediatric inflammatory diseases without uveitis; and to determine the correlation between these PG signatures, microbiota composition, and disease parameters in the context of uveitis.
Participants will be informed about the study during their routine follow-up visits.
These procedures do not require any additional medical procedures or visits beyond routine follow-up.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,576 studies on the registry; 1,028 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
including pediatric connective tissue disorders, granulomatosis, idiopathic juvenile arthritis without uveitis, pediatric vasculitis, and chronic inflammatory bowel diseases. These conditions were selected because of their inflammatory and/or autoimmune nature, making it possible to determine whether fecal peptidoglycan signatures
without uveitis (connective tissue disease, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitis, chronic inflammatory bowel disease)
Siblings of patients or children of hospital staff, who may be included as healthy control groups
fecal peptidoglycans
the composition and relative abundance of fecal PG fragments in children with uveitis compared to healthy children.
Time frame: Day 1
Gut Microbiome
* Correlations between the peptidoglycans and the gut microbiota, as determined by sequencing. * Analysis of fecal microRNAs (miRNAs) and their correlations with the peptidoglycans and the microbiota. * Analysis of associations between the peptidoglycans and the microbiota, miRNAs, and clinical parameters: uveitis activity, ophthalmic complications, and patient metadata. * Comparison with the additional control group (non-ocular inflammatory diseases) to identify signatures specific to uveitis versus those associated with a systemic inflammatory condition.
Time frame: Day 1
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →